Experts in high-risk pregnancy respond to the published results of the PROLONG trial

October 25, 2019

The Society for Maternal-Fetal (SMFM) released the following statement in response to the published results of "Progestin's Role in Optimizing Neonatal Gestation," more commonly referred to as the PROLONG trial, which was recently published in the American Journal of Perinatology.

"The PROLONG trial assessed the effectiveness of weekly injections of 17-alpha-hydroxyprogesterone caproate (17-OHPC) in reducing the incidence of recurrent preterm birth and neonatal morbidity. Between 2009 and 2018, this study enrolled more than 1,700 pregnant patients from nine countries and ultimately concluded that 17-OHPC does not decrease recurrent preterm birth or neonatal morbidity.

A previous large randomized control trial (Meis, 2003) also examined the effectiveness of 17-OHPC. Unlike PROLONG, this study found a 34% reduction in the incidence of recurrent preterm birth and significant reductions in several neonatal complications.

In comparing the conflicting results of the PROLONG and Meis trials, one important consideration is the different populations studied. The Meis trial included a larger proportion of patients with additional risk factors for preterm birth. For example, 20% of the patients in the Meis trial reported smoking, compared to 8% in the PROLONG Trial. Other meaningful differences in the populations included:SMFM has reviewed the results of the PROLONG trial and has released the SMFM Statement: Use of 17-alpha hydroxyprogesterone caproate for prevention of recurrent preterm birth, which recommends that obstetric care providers use an individualized approach as they council patients regarding the use of 17-OHPC. It is reasonable for providers to continue to use 17-OHPC in the context of a shared decision-making model that includes consideration of risk level for recurrent PTB. Important factors to discuss include: uncertainly regarding the benefit, the lack of short-term safety concerns, the possibility of injection site pain, extra patient visits, and substantial costs.

Further, SMFM recommends additional research on 17-OHPC to identify populations in whom it is likely to be effective.
-end-
SMFM's complete, updated clinical guidance will be published in the American Journal of Obstetrics and Gynecology, can be found on the SMFM website, and will be addressed on Tuesday, October 29, 2019 at meeting of the Food and Drug Administration's Bone, Reproductive and Urologic Drugs Advisory Committee.

Society for Maternal-Fetal Medicine

Related Preterm Birth Articles from Brightsurf:

Researchers develop app to determine risk of preterm birth
An improved mobile phone app will help identify women who need special treatments at the right time and reduce emotional and financial burden on families and the NHS.

Point-of-care diagnostic for detecting preterm birth on horizon
A new study provides a first step toward the development of an inexpensive point-of-care diagnostic test to assess the presence of known risk factors for preterm birth in resource-poor areas.

WVU biostatistician studies link between microbiome and preterm birth
Pregnant African American women are more likely than white women to give birth prematurely, but they're underrepresented in studies of preterm birth rates.

3D-printed device detects biomarkers of preterm birth
Preterm birth (PTB) -- defined as birth before the 37th week of gestation -- is the leading complication of pregnancy.

Association of quitting smoking during pregnancy, risk of preterm birth
This study of more than 25 million pregnant women reports on rates of smoking cessation at the start of and during pregnancy and also examines the association of quitting cigarette smoking and the risk of preterm birth.

Blood test developed to predict spontaneous preterm birth
Results from a multicenter study show that five circulating microparticle proteins found in first-trimester blood samples may provide important clues about risk of spontaneous preterm birth.

Scientists gain new insight on triggers for preterm birth
A group of scientists led by Ramkumar Menon at The University of Texas Medical Branch at Galveston have gained new insight on a poorly-understood key player in the timing of labor and delivery.

Medically assisted reproduction does not raise risk of preterm birth and low birth weight
Study shows that couples can decide about using medically assisted reproduction free from concerns about increasing the health risks to their baby.

Risk of preterm birth reliably predicted by new test
Scientists at UC San Francisco have developed a test to predict a woman's risk of preterm birth when she is between 15 and 20 weeks pregnant, which may enable doctors to treat them early and thereby prevent severe complications later in the pregnancy.

Preterm birth leaves its mark in the functional networks of the brain
Researchers at the University of Helsinki and the Helsinki University Hospital, Finland, have proven that premature birth has a significant and, at the same time, a very selective effect on the functional networks of a child's brain.

Read More: Preterm Birth News and Preterm Birth Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.